Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks .

What is Onconova Therapeutics' stock price target for 2024?

1 brokerages have issued 12-month price objectives for Onconova Therapeutics' stock. Their ONTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,472.8% from the stock's current price. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts .

How have ONTX shares performed in 2023?

Onconova Therapeutics' stock was trading at $0.6457 on January 1st, 2023. Since then, ONTX stock has increased by 8.3% and is now trading at $0.6994. View the best growth stocks for 2023 here .

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 85,500 shares, an increase of 21.1% from the October 31st total of 70,600 shares. Based on an average daily trading volume, of 70,800 shares, the short-interest ratio is currently 1.2 days. View Onconova Therapeutics' Short Interest .

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ONTX earnings forecast .

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the previous year, the business earned ($0.45) EPS.

When did Onconova Therapeutics' stock split?

Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Tonix Pharmaceuticals (TNXP) , Acasti Pharma (ACST) , Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM) .

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler , James J Marino , Mark Patrick Guerin and Steven M Fruchtman . View institutional ownership trends .

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Onconova Therapeutics Stock Price, News & Analysis (NASDAQ:ONTX)

$0.70

+0.01 (+1.45%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.69
▼
$0.70
50-Day Range: $0.62
▼
$0.74
52-Week Range: $0.55
▼
$1.49

Volume: 40,313 shs
Average Volume: 51,270 shs
Market Capitalization: $14.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Onconova Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,472.8% Upside
$11.00 Price Target
Short Interest: Healthy
0.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.87
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to ($0.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

729th out of 951 stocks

Pharmaceutical Preparations Industry

336th out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Onconova Therapeutics has a forecasted upside of 1,472.8% from its current price of $0.70.
Amount of Analyst Coverage
Onconova Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.41% of the outstanding shares of Onconova Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Onconova Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Onconova Therapeutics has recently increased by 21.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Onconova Therapeutics does not currently pay a dividend.
Dividend Growth
Onconova Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONTX.

2.7

News and Social Media Coverage

News Sentiment
Onconova Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Onconova Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Onconova Therapeutics is held by insiders.
Percentage Held by Institutions
Only 8.85% of the stock of Onconova Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Onconova Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Onconova Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Onconova Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Onconova Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONTX Stock News Headlines

November 28, 2023 | finance.yahoo.com

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

November 24, 2023 | americanbankingnews.com

Onconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.com

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 16, 2023 | finance.yahoo.com

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript

November 16, 2023 | finanznachrichten.de

Onconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

November 7, 2023 | finance.yahoo.com

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

November 2, 2023 | benzinga.com

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 2, 2023 | finance.yahoo.com

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

October 19, 2023 | markets.businessinsider.com

Promising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An Analysis

October 19, 2023 | finance.yahoo.com

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

October 12, 2023 | marketwatch.com

Onconova Therapeutics Shares Rise 12% On Skin Cancer Treatment Data

October 12, 2023 | finance.yahoo.com

Encouraging Rigosertib Data Presented at EADV as Late Breaker

September 28, 2023 | finance.yahoo.com

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

September 6, 2023 | finance.yahoo.com

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Onconova Therapeutics (ONTX)

August 11, 2023 | finance.yahoo.com

Q2 2023 Onconova Therapeutics Inc Earnings Call

August 10, 2023 | finance.yahoo.com

Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

July 17, 2023 | finance.yahoo.com

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

June 14, 2023 | finance.yahoo.com

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

June 7, 2023 | msn.com

HC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Prior Recommendation

June 6, 2023 | markets.businessinsider.com

Onconova Therapeutics (ONTX) Receives a Buy from H.C. Wainwright

June 5, 2023 | finance.yahoo.com

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

May 25, 2023 | finance.yahoo.com

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

May 17, 2023 | marketwatch.com

8-K: Onconova Therapeutics, Inc.

See More Headlines

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ONTX
CUSIP: N/A
CIK: 1130598
Web: www.onconova.com
Phone: (267) 759-3680
Fax: 267-759-3681
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +1,472.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,960,000.00
Net Margins: -8,930.97%
Pretax Margin: -8,930.97%
Return on Equity: -95.43%
Return on Assets: -61.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.79
Quick Ratio: 2.79

Sales & Book Value

Annual Sales: $226,000.00
Price / Sales: 65.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.69 per share
Price / Book: 1.01

Miscellaneous

Outstanding Shares: 21,003,000
Free Float: 20,310,000
Market Cap: $14.69 million
Optionable: Not Optionable
Beta: 1.70

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Steven M. Fruchtman M.D. (Age 72)
CEO, President & Director
Comp: $907.86k
Mr. Mark Patrick Guerin CPA (Age 54)
CFO & COO
Comp: $629.27k
Dr. Adar Makovski Silverstein Ph.D.
Senior Director & Head of Corporate Development
Dr. Victor Moyo M.D.
Chief Medical Officer

Key Competitors

View All Competitors

ONTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings or view top-rated stocks.
What is Onconova Therapeutics' stock price target for 2024?: 1 brokerages have issued 12-month price objectives for Onconova Therapeutics' stock. Their ONTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,472.8% from the stock's current price.
View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts.
How have ONTX shares performed in 2023?: Onconova Therapeutics' stock was trading at $0.6457 on January 1st, 2023. Since then, ONTX stock has increased by 8.3% and is now trading at $0.6994.
View the best growth stocks for 2023 here.
Are investors shorting Onconova Therapeutics?: Onconova Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 85,500 shares, an increase of 21.1% from the October 31st total of 70,600 shares. Based on an average daily trading volume, of 70,800 shares, the short-interest ratio is currently 1.2 days.
View Onconova Therapeutics' Short Interest.
When is Onconova Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ONTX earnings forecast.
How were Onconova Therapeutics' earnings last quarter?: Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the previous year, the business earned ($0.45) EPS.

When did Onconova Therapeutics' stock split?: Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Onconova Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).
Who are Onconova Therapeutics' major shareholders?: Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, James J Marino, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends.
How do I buy shares of Onconova Therapeutics?: Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ONTX) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial